Pooled analysis demonstrates the safety of intravitreal bevacizumab gamma in eyes with neovascular age-related macular degeneration, suggesting its efficacy.
Purpose: To analyse pooled safety data of intravitreal bevacizumab gamma across all trials included within the NORSE clinical programme for nAMD. Methods: Post-hoc safety analysis included all eyes receiving ≥1 intravitreal injection of bevacizumab gamma for nAMD across the NORSE clinical [for full text, please go to the a.m. URL]
No takes yet. Share an insight, caveat, or question.
Khoramnia et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: